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Abstract
Background:  Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have
neuroprotective effects in experimental stroke models and are commonly prescribed in clinical
practice. The aim of this study was to determine if patients taking statins before hospital admission
for stroke had an improved clinical outcome.
Methods: This was an observational study of 436 patients admitted to the National Institutes of
Health Suburban Hospital Stroke Program between July 2000 and December 2002. Self-reported
risk factors for stroke were obtained on admission. Stroke severity was determined by the
admission National Institutes of Health Stroke Scale score. Good outcome was defined as a Rankin
score < 2 at discharge. Statistical analyses used univariate and multivariate logistic regression
models.
Results: There were 436 patients with a final diagnosis of ischemic stroke; statin data were
available for 433 of them. A total of 95/433 (22%) of patients were taking a statin when they were
admitted, rising from 16% in 2000 to 26% in 2002. Fifty-one percent of patients taking statins had
a good outcome compared to 38% of patients not taking statins (p = 0.03). After adjustment for
confounding factors, statin pretreatment was associated with a 2.9 odds (95% CI: 1.2–6.7) of a good
outcome at the time of hospital discharge.
Conclusions: The proportion of patients taking statins when they are admitted with stroke is
rising rapidly. Statin pretreatment was significantly associated with an improved functional outcome
at discharge. This finding could support the early initiation of statin therapy after stroke.
Background
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, which converts HMG-CoA to
mevalonate, a precursor of cholesterol, and are widely
used for the treatment of hypercholesterolemia. These
agents have also been proven to significantly reduce the
risk of heart attack and stroke in patients with proven cor-
onary artery disease [1-4]. They have also been shown to
reduce the risk of transient ischemic attack (TIA) but not
stroke in elderly individuals at risk of vascular disease [5].
Some of these cardiovascular protective effects may be
through mechanisms other than lipid lowering, including
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the modification of endothelial function, anti-inflamma-
tory effects, increased plaque stability, and reduction in
thrombus formation [6,7].
Because statins are increasingly being prescribed for lipid
lowering and secondary prevention in patients with coro-
nary heart disease, it is likely that an increasing number of
patients will be taking statins when they suffer a stroke.
This rate is likely to further increase with the report of the
Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Low-
ering Arm (ASCOT-LLA) – study showing a protective
effect of statins in elderly hypertensive patients with aver-
age cholesterol concentrations [8]. In experimental stroke
models, statins have been reported to reduce infarct size
and exert neuroprotective effects independently of the
serum cholesterol level, as well as to enhance functional
recovery after stroke [9-12]. These are postulated to be
through anti-inflammatory effects and modification of
endothelial function, in addition to angiogenesis, neuro-
genesis and synaptogenesis [9,10,12-14]. Statins may lead
to up-regulation of endothelial nitric oxide which aug-
ments cerebral blood flow [9,10]. Further, withdrawal of
statins has been shown to abrogate stroke neuroprotec-
tion [15]. Statins have been reported to protect against
stroke events in stroke-prone spontaneously-hypertensive
rats and ameliorate stroke severity by inhibition of super-
oxide production and modulation of inflammation in the
brain [11].
The effect of statins on stroke severity and outcome has
not been comprehensively studied in human stroke. We
hypothesized that patients with ischemic stroke who were
taking statins before admission to hospital would have a
better outcome on hospital discharge.
Methods
Study design
This was an observational study of consecutive patients
admitted to the National Institutes of Health (NIH)
Stroke Program at Suburban Hospital, Bethesda, MD,
between June 2000 and December 2002 [16]. A total of
577 patients in the stroke registry and their medical
records were reviewed. All patients had given informed
consent to the use of their medical records. Of those 577,
436 (75.6%) had a final diagnosis of ischemic stroke, 89
(15.4%) patients had transient ischemic attack (TIA), and
52 (9.0%) had intracranial hemorrhage (ICH). Exclusion
criteria were age less than 18 years, ICH, TIA, and patients
with in-hospital stroke.
Patient data
Self-reported or family-reported risk factors for stroke
were obtained on admission. These were hypertension,
diabetes mellitus, coronary artery disease, atrial fibrilla-
tion, hypercholesterolemia, previous stroke, previous TIA,
history of infection one week prior to the stroke onset,
and cancer (defined as history of treatment). Smoking was
classified into: current smoker, former smoker, and non
smoker. Some relevant medications patients were taking
prior to admission were also recorded; these were statins,
other lipid lowering drugs, and antiplatelet (aspirin,
clopidogrel, aspirin-dipyridamole combination, ticlopi-
dine), and anticoagulant (coumadin) therapies. The
admission National Institutes of Health Stroke Scale
(NIHSS) score [17,18] and discharge NIHSS score were
prospectively measured. The NIHSS score was categorized
into three clinically accepted levels (<6 [mild], 6–15
[medium], >15 [severe]) for the statistical analyses. Sub-
types of ischemic stroke [19] were reviewed at the time of
discharge. The modified Rankin scale [20,21], recorded at
the time of admission and providing a measure of pre-
stroke morbidity, was available in 281 patients.
Peripheral blood markers
Non-fasting total serum cholesterol, high-density lipopro-
tein (HDL), low-density lipoprotein (LDL), triglycerides
(TG), and white blood cell (WBC) and platelet counts
were measured immediately after admission to hospital.
The median time of the blood sample was 3.0 hours after
the onset of stroke symptoms (range: 0.15–127 hours).
Outcome assessment
The modified Rankin score was recorded at the time of
hospital discharge (n = 393). The median length of stay
was five days. Good outcome was defined as a discharge
modified Rankin scale score < 2.
Data analysis
Continuous data are presented as means with standard
deviations (SD), and categorical data are presented as fre-
quencies and percentages. Student t-tests and the Wil-
coxon Rank-Sum test were used for bivariate analyses of
continuous data. Differences between proportions were
evaluated by the χ2 test or Fisher's exact tests. To identify
potential confounding variables for clinical outcome after
stroke (discharge Rankin scale < 2), multivariate logistic
regression modeling was used. All variables significantly
associated with outcome in univariate analysis were
included in the multivariate model. Cases with missing
data were excluded. Two-tailed significance tests were
used, and a probability value of 0.05 was considered sig-
nificant in both univariate and multivariate analyses. Sta-
tistical analyses were performed with the use of the
statistical program SAS version 8.2 (SAS Institute Inc.,
Cary, NC, USA).
Results
There were 436 patients with a final diagnosis of ischemic
stroke, 228 (52.3%) of whom were female. The mean age
of the patients was 74.8 ± 14.2 years.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/4
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Statin use
Data on statin use were available in 433 patients, 95 of
whom (22%) were taking a statin when they were admit-
ted to the hospital (Figure 1). The rate of statin pretreat-
ment increased from 9/56 (16%) in 2000, to 29/161
(18%) in 2001, and 57/216 in 2002 (26%). Only one
patient was taking a non-statin drug for lipid lowering
(gemfibrozil). The statin used was simvastatin (41
patients), atorvastatin (37 patients), pravastatin (nine
patients), lovastatin (three patients), cerivastatin (one
patient), and unknown (four patients). The overall cho-
lesterol and LDL values were low in this population, with
a mean cholesterol value of 191.4 ± 45.2 mg/dL and LDL
value of 111.8 ± 39.4 mg/dL. Compliance with statin use
was not available, but lower LDL and cholesterol values
were seen in patients taking statins.
Hypertension (p < 0.06), diabetes mellitus (p < 0.02), cor-
onary artery disease (p < 0.001), and infection during the
week prior to stroke onset (p < 0.009) were more common
among patients who were taking statins at this time. The
rate of preceding infection was 13% in patients taking
statins compared to 5% in those not; the corresponding
total white blood cell count values in patients with an
infection prior to stroke onset were 12.9 ± 7.0 for patients
taking statins and 14.2 ± 15.1 for patients not taking stat-
ins (p = 0.27). Patients who were on statins were more
likely to be receiving anticoagulant and/or antiplatelet
therapy at the time of stroke admission (p < 0.001, Table
1). A total of 76/161 (47%) of patients with a history of
hyperlipidemia were taking statins, while 45/104 (43%)
of patients with a history of carotid disease were taking
statins. There was no difference in admission Rankin score
(measure of prestroke disability) between patients on stat-
ins prior to stroke onset and patients not taking statins.
Stroke severity, as measured by the admission NIHSS
score, was constant over the two and a half year period of
the study, the median value being 4.0 (range 9–33). There
was no significant difference in stroke severity between
patients taking statins and those not (p = 0.50). There was
also no significant difference between statin use and
ischemic stroke subtype by TOAST classification (p = 0.4).
Stroke outcome
Table 2 shows the association between clinical factors and
clinical outcome. Data on the discharge Rankin score were
available in 393 patients. One hundred and sixty-one
(41.0%) patients had a good outcome (Rankin score < 2
at discharge). The proportion of patients taking statins
and achieving a good outcome was 43/84 (51.2%) com-
pared to 118/309 (38.2%) for patients not taking statins
(p= 0.03). The other factors associated with good outcome
at discharge were younger age (p < 0.001), lower admis-
sion NIHSS score (p < 0.001), no history of prior stroke (p
< 0.001) and lower total white cell count (p < 0.001), no
history of hypertension (p = 0.003), atrial fibrillation (p =
0.05) or hyperlipidemia (p = 0.005), and male gender (p
= 0.02). The mortality rate for patients taking statins was
6/84 (7.1%) compared to 30/309 (9.7%) for patients not
taking statins (p = 0.70). There was no significant relation-
ship between outcome and total serum cholesterol, HDL,
LDL, or cholesterol/HDL.
All of these variables were entered into the multivariate
analysis. The logistic regression model for good outcome
(discharge modified Rankin score < 2) is shown in Table
3. Statins still had a beneficial effect on outcome with an
odds ratio of 2.9 (95% CI: 1.2–6.7).
Discussion
Prior statin use is becomingly increasingly common in
patients admitted with stroke. With further reports of the
beneficial effects of statins on stroke prevention in elderly
individuals with hypertension and vascular disease [5,8],
this trend can be expected to continue. This study suggests
that statins may have a protective effect on stroke outcome
at discharge, although the effect is much less significant
than that reported in experimental stroke models. Older
age, increased WBC and higher admission NIHSS score
Data on statin use were available in 433 patients, 95 of whom  (22%) were taking a statin when they were admitted to the  hospital Figure 1
Data on statin use were available in 433 patients, 95 of whom 
(22%) were taking a statin when they were admitted to the 
hospital. During the hospital admission, statins had been dis-
continued in 50 of these 95 patients for clinical indications, 
while 56 of the 338 patients who had not been pretreated 
with statins were taking statins by the time of hospital dis-
charge. The variable commencement and duration of statin 
treatment in-hospital and the variable length of stay made it 
very difficult to definitively assess any effectiveness of statin 
treatment over the short in-hospital period (median length of 
hospitalization: 5.0 days).
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Table 1: Demographic and clinical characteristics of the patients (n = 433)
Treatment with statins
Variables Yes (n = 95) No (n = 338) p
(mean ± SD)
Age, years 75.4 ± 9.1 74.6 ± 15.3 0.62
WBC, Thou/uL 8.6 ± 3.8 8.6 ± 4.5 0.97
Platelet, Thou/uL 250.9 ± 76.7 254.8 ± 86.5 0.70
Cholesterol, mg/dL 181.2 ± 83.7 196.5 ± 46.1 0.03
HDL, mg/dL 49.7 ± 17.1 52.3 ± 17.0 0.22
LDL, mg/dL 94.0 ± 29.2 116.9 ± 40.5 <0.0001
TG, mg/dL 152.6 ± 102.2 140.9 ± 97.1 0.33
N (%)
Sex – Women 43 (45) 184 (54) 0.13
Race – Caucasian 83 (87) 287 (85) 0.12
Hypertension 73 (77) 225 (67) 0.06
Diabetes mellitus 27 (28) 59 (17) 0.02
Coronary artery disease 45 (47) 58 (17) <0.001
Atrial fibrillation 18 (19) 62 (18.4) 0.94
Smoking 19 (19) 87 (25.9) 0.54
Hyperlipidemia 76 (80) 84 (25) <0.001
Previous stroke 26 (27) 81 (24) 0.50
Previous TIA 16 (17) 37 (11) 0.16
Prior history of cancer 19 (20) 49 (15) 0.20
History of infection 12 (13) 17 (5) 0.009
Antiplatelet/anticoagulant 63 (66) 145 (43) <0.001
Admission NIHSS 0.4
<6 57 (62.0) 181 (57.8)
6–15 20 (21.7) 74 (23.6)
>15 15 (16.3) 58 (18.5)
Admission Rankin scale < 2 57 (77.0) 158 (76.3) 0.9
WBC, white blood cell; HDL, high-density lipoprotein; LDL; low-density lipoprotein; TG, triglyceride; TIA, transient ischemic attack.
Table 2: Association between prognostic factors and discharge Rankin scale by univariate analysis
Factor Discharge Rankin scale < 2 Discharge Rankin scale ≥ 2
(n = 161) (n = 232)
mean ± SD
Age, y* 69.2 ± 14.6 78.1 ± 12.3
WBC count, Thou/uL* 7.4 ± 2.3 9.5 ± 5.3
N (%)
Sex†
Women 72 (44.7) 133 (57.3)
Hypertension† 98 (60.9) 175 (75.4)
Hyperlipidemia† 72 (44.7) 73 (31.5)
Previous stroke† 27 (16.8) 71 (30.7)
Statins† 43 (26.7) 41 (17.7)
Antiplatelet and/or anticoagulant 81 (50.6) 111 (47.8)
Admission NIHSS score†
<6 134 (87.0) 85 (39.7)
6–15 17 (11.0) 66 (30.8)
>15 3 (2.0) 63 (29.4)
Admission Rankin scale < 2† 115 (60.2) 76 (39.8)
*All comparisons were significant after Bonferroni correction for multiple comparisons. †Fisher's Exact test, p < 0.05. WBC, white blood cell.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/4
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were also very significant outcome predictors in this eld-
erly population. These factors might help explain in part
why experimental stroke models may not always directly
translate into human stroke.
In this study it was not possible to determine if, or how
many, strokes were avoided by the use of statins, or if any
potential strokes were converted into TIAs or vice versa.
Only a large population study of all individuals taking
statins could answer this question. The greater rate of
stroke risk factors such as coronary artery disease and dia-
betes may also offset any beneficial effects of statins on
stroke risk and severity. One previous study in humans
investigated the effect of pretreatment with statins [22] on
stroke outcome and reported a borderline trend to better
outcome at hospital discharge (early discharge to home).
However, this prior study did not distinguish between
hemorrhagic and ischemic stroke, and only 8.3% of
patients were taking statins. Further, the cohort was
younger (mean age 66 years) and the type of statin was
not reported. In a preliminary analysis from the Heart and
Estrogen Progestin Replacement Study (HERS) [23],
reduced mortality in stroke patients with a history of sta-
tin use has been reported; in the current study lower mor-
tality was also seen, but not significantly.
An improved functional outcome at discharge in patients
already taking statins when admitted to hospital could
argue for the early initiation of statin therapy after stroke
in those not already taking them. In this study there were
56/338 patients not pretreated with statins but who had
been commenced on statins by the time of hospital dis-
charge. The variable commencement and duration of sta-
tin treatment in hospital and the variable length of stay
made it very difficult to definitively assess any effective-
ness of statin treatment over the short in-hospital period
(median length of hospitalization: 5.0 days). In a recent
conference report [24] in a large cohort from the Citico-
line trial, early initiation of statin treatment in the first two
weeks of stroke was associated with better outcome,
although no significant effect of statin usage pre-stroke on
outcome was found. There have been a number of reports
of the early initiation of statin treatment after myocardial
infarction (MI), but to date the results are conflicting.
Observational studies in coronary artery disease demon-
strated that patients who are treated with a statin early
after a coronary event have a more favorable outcome
than those who are not [25,26]. Early statin treatment in
patients with acute MI has been associated with a reduc-
tion in one-year mortality [27]. In a recent study, however,
early statin initiation after acute coronary syndromes
failed to demonstrate improved outcome [28].
The overall cholesterol and LDL levels were close to the
normal range in this study. Of note was that there was no
correlation between serum cholesterol and LDL with
stroke severity and outcome, possibly indicating that the
beneficial effects of statins were independent of lipid low-
ering. The higher rate of preceding infection in patients
taking statins may be an indication of immune modula-
tion by statins [10,29]. The role of white cell count and
inflammation on outcome should be further studied as
this was a factor associated with poor outcome [28].
It has recently been reported that even in patients with
proven indications for statin therapy (such as hypercho-
lesterolemia or coronary artery disease), statins are highly
underutilized [30]. The statins that were mainly used in
our study were simvastatin and atorvastatin. These are
hydrophobic statins. The hydrophilic statin pravastatin
has the most evidence for secondary prevention of cardiac
events [31]; however only a few of our patients were tak-
ing this medication. This study has some limitations: a ret-
rospective registry study may not adjust for all
confounders such as type and length of statin treatment,
outpatient compliance and efficacy of lipid lowering. It
may be argued that patients with a final diagnosis of TIA
were excluded from the study. However the proportion of
patients with TIA who were taking statins (19.1%) was
similar to the proportion of ischemic stroke patients tak-
ing statins (21.8%).
Conclusion
Over the two and a half year period of the study, statin use
increased, and was associated with improved stroke out-
come. Pretreatment with statins was significantly associ-
ated with better outcome after the ischemic stroke. These
effects seemed to be independent of lipid lowering and
some possible immune modulatory effects of statins were
noted. To confirm the effectiveness of pretreatment with
statins on clinical outcome after stroke, a large rand-
omized clinical trial study could be undertaken.
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Table 3: Independent predictors of discharge Rankin scale (<2) in 
the multivariate logistic regression model
Factor OR 95% CI p
Age 2.7 1.7–4.3 <0.0001
NIHSS score 7.2 3.5–14.8 <0.0001
WBC count 3.5 1.2–10.1 0.02
Statins 2.9 1.2–6.7 0.02
OR, odds ratio; 95% CI, 95% confidence interval; NIHSS, National 
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